Ypsomed Holding AG

YPSN

Equity

ISIN CH0019396990 / Valor 1939699

SIX Swiss Exchange (2024-11-20)

CHF 344.00-1.43%

Ypsomed Holding AG
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Ypsomed Holding AG is a company that operates through its subsidiary Ypsomed Delivery Systems (YDS), which offers a range of technologies and services for injection systems used in self-medication. YDS caters to pharmaceutical and biotechnology companies that develop, manufacture, and market injectable therapies. Additionally, Ypsomed provides a comprehensive portfolio of products and services under the mylife Diabetescare brand, aimed at individuals with diabetes to facilitate easy, discreet, and reliable self-treatment. Through its offerings, Ypsomed aims to simplify and improve the self-treatment experience for its users.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the first half of the 2023/24 financial year, Ypsomed Holding AG achieved consolidated sales of CHF 255.4 million. Adjusted for the divestment of DiaExpert, this corresponds to a comparable growth of 24% for the continued business.

EBIT Performance

Ypsomed Holding AG reported an EBIT of CHF 39.9 million for the first half of the 2023/24 financial year. This represents a significant increase from the CHF 19.4 million reported in the same period of the previous year.

Diabetes Care Segment

Ypsomed Holding AG's Diabetes Care segment saw exceptional demand for the mylife Loop offering, leading to a more than 150% increase in commercial sales of the YpsoPump in the first half of the 2023/24 financial year.

New Contracts

Ypsomed Holding AG signed a significant long-term supply contract with Novo Nordisk in the field of metabolic diseases. Although this contract will not contribute commercially for another two years, it represents a substantial milestone for the company's growth strategy.

International Expansion

Ypsomed Holding AG is pushing ahead with its international expansion, having submitted the approval dossier for the mylife Loop in Canada and planning to apply for FDA approval for the YpsoPump in the USA in the coming months.

Summarized from source with an LLMView Source

Key figures

22.2%1Y

92.3%3Y

157%5Y

Performance

30.3%1Y

31.6%3Y

31.1%5Y

Volatility